These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 25594497)

  • 1. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
    Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
    J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The unbinding studies of vascular endothelial growth factor receptor-2 protein tyrosine kinase type II inhibitors.
    Kang CM; Liu DQ; Wang XY; Yu RL; Lv YT
    J Mol Graph Model; 2015 Jun; 59():130-5. PubMed ID: 25989626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of triazine derivatives as ROCK1 inhibitors: molecular docking, molecular dynamics simulations and free energy calculations.
    Shen M; Zhou S; Li Y; Pan P; Zhang L; Hou T
    Mol Biosyst; 2013 Mar; 9(3):361-74. PubMed ID: 23340525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies of N(9)-arenthenyl purines as novel DFG-in and DFG-out dual Src/Abl inhibitors using 3D-QSAR, docking and molecular dynamics simulations.
    Ma S; Zeng G; Fang D; Wang J; Wu W; Xie W; Tan S; Zheng K
    Mol Biosyst; 2015 Feb; 11(2):394-406. PubMed ID: 25406390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based identification of potent VEGFR-2 inhibitors from in vivo metabolites of a herbal ingredient.
    Dash R; Junaid M; Mitra S; Arifuzzaman M; Hosen SMZ
    J Mol Model; 2019 Mar; 25(4):98. PubMed ID: 30904971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore based 3D-QSAR modeling and free energy analysis of VEGFR-2 inhibitors.
    Rajagopalan M; Balasubramanian S; Ramaswamy A; Mathur PP
    J Enzyme Inhib Med Chem; 2013 Dec; 28(6):1236-46. PubMed ID: 23061928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dynamics simulation, free energy calculation and structure-based 3D-QSAR studies of B-RAF kinase inhibitors.
    Yang Y; Qin J; Liu H; Yao X
    J Chem Inf Model; 2011 Mar; 51(3):680-92. PubMed ID: 21338122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
    Zhao H; Huang D; Caflisch A
    ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Importance of protein flexibility in ranking inhibitor affinities: modeling the binding mechanisms of piperidine carboxamides as Type I1/2 ALK inhibitors.
    Kong X; Pan P; Li D; Tian S; Li Y; Hou T
    Phys Chem Chem Phys; 2015 Feb; 17(8):6098-113. PubMed ID: 25644934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
    Gao C; Grøtli M; Eriksson LA
    J Mol Model; 2015 Jul; 21(7):167. PubMed ID: 26044359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dynamics-based insight of VEGFR-2 kinase domain: a combined study of pharmacophore modeling and molecular docking and dynamics.
    Parves MR; Riza YM; Alam S; Jaman S
    J Mol Model; 2022 Dec; 29(1):17. PubMed ID: 36550239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
    Yang Y; Shen Y; Liu H; Yao X
    J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors.
    Modi SJ; Kulkarni VM
    J Biomol Struct Dyn; 2022 Aug; 40(12):5712-5727. PubMed ID: 33459187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
    Tripathi SK; Muttineni R; Singh SK
    J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, Synthesis, Docking, DFT, MD Simulation Studies of a New Nicotinamide-Based Derivative: In Vitro Anticancer and VEGFR-2 Inhibitory Effects.
    Elkaeed EB; Yousef RG; Elkady H; Gobaara IMM; Alsfouk BA; Husein DZ; Ibrahim IM; Metwaly AM; Eissa IH
    Molecules; 2022 Jul; 27(14):. PubMed ID: 35889478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insight into the Binding of DFG-out Allosteric Inhibitors to B-Raf Kinase Using Molecular Dynamics and Free Energy Calculations.
    Coronel L; Granadino-Roldán JM; Pinto M; Tomas MS; Pujol MD; Rubio-Martinez J
    Curr Comput Aided Drug Des; 2015; 11(2):124-36. PubMed ID: 26135342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular simulation studies to reveal the binding mechanisms of shikonin derivatives inhibiting VEGFR-2 kinase.
    Munni YA; Ali MC; Selsi NJ; Sultana M; Hossen M; Bipasha TH; Rahman M; Uddin MN; Hosen SMZ; Dash R
    Comput Biol Chem; 2021 Feb; 90():107414. PubMed ID: 33191109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation.
    Wang Y; Peng C; Wang G; Xu Z; Luo Y; Wang J; Zhu W
    Chem Biol Drug Des; 2019 May; 93(5):934-948. PubMed ID: 30689282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular dynamics guided insight, binding free energy calculations and pharmacophore-based virtual screening for the identification of potential VEGFR2 inhibitors.
    Rathi E; Kumar A; Kini SG
    J Recept Signal Transduct Res; 2019; 39(5-6):415-433. PubMed ID: 31755336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A molecular dynamics investigation of CDK8/CycC and ligand binding: conformational flexibility and implication in drug discovery.
    Cholko T; Chen W; Tang Z; Chang CA
    J Comput Aided Mol Des; 2018 Jun; 32(6):671-685. PubMed ID: 29737445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.